Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00298012
Other study ID # 2005-001202-60
Secondary ID
Status Withdrawn
Phase Phase 4
First received February 28, 2006
Last updated January 2, 2009
Start date March 2006

Study information

Verified date January 2009
Source Rheumatism Foundation Hospital
Contact n/a
Is FDA regulated No
Health authority Finland: Finnish Medicines Agency
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.


Description:

The established classification criteria for ankylosing spondylitis (AS) rely on the combination of clinical symptoms plus radiographic sacroiliitis of at least grade 2 bilaterally or grade 3 unilaterally. It usually takes several years for definite radiographic sacroiliitis to evolve. Diagnosis of AS may be delayed up to 10 years after the onset of symptoms, if diagnosis is based on the radiographic findings.

A group of leading experts in the field of spondyloarthropathies proposed in 2004 the term "axial spondyloarthritis" as an attempt to narrow the gap of 5-10 years between the first symptoms and the diagnosis of AS (Rudwaleit et al. Ann Rheum Dis 2004; 63:535-43). Using the proposed approach, an early diagnosis of AS (or axial spondyloarthritis) can be made with a high degree of confidence, when at least two to three spondyloarthritis features (clinical findings, laboratory tests or skeletal imaging) are present. Magnetic resonance imaging (MRI) of the sacroiliac joints appears to be especially useful tool in the diagnosis of early AS. Early diagnosis and treatment could probably prevent structural damage and lead to better functional outcomes.

Treatment of AS has largely consisted of non-steroidal anti-inflammatory drugs (NSAIDs). Most disease modifying antirheumatic drugs are not effective in axial manifestations. Sulfasalazine has some efficacy on peripheral symptoms. Tumor necrosis factor (TNF) alpha blocking drugs infliximab and etanercept are effective in both axial and peripheral manifestations of the disease. According to consensus statement, the initiation of anti-TNF alpha therapy requires a definitive diagnosis of AS, which is based on radiographic evidence of sacroiliitis.

It is well documented, that oral methotrexate is effective and safe in the treatment of rheumatoid arthritis and psoriatic arthritis. Still, studies proving its usefulness for the treatment of AS are lacking. To this date, three small randomised and controlled trials to clarify this issue have been conducted. The dose of methotrexate used in these studies was low, only 7,5 - 10 mg per week. One of these studies showed a benefit in the active treatment group. There was no statistically significant benefit of methotrexate in the two other studies.

The purpose of this study is to assess the efficacy of oral methotrexate in adult subjects with active axial spondyloarthritis. Subjects will be randomly assigned to placebo or methotrexate treatment groups. All subjects in the active treatment group receive at least a dose of 15 mg per week of oral methotrexate. To reduce mucosal, gastrointestinal and haematologic side effects of low-dose methotrexate all study subjects receive also a dose of 5 mg per week of folic acid. A stable dose of NSAID during the study is permitted. The duration of the double-blinded treatment period is 24 weeks.

Efficacy of the treatment is measured by reduction in the signs and symptoms of axial spondyloarthritis at weeks 12 and 24. If the primary outcome of ASAS20 (ASsessment in Ankylosing Spondylitis response criteria, improvement of at least 20 % in patient reported symptoms) is not met at the week 12, the dose of methotrexate or corresponding placebo will be increased to 20 mg per week during weeks 12 to 24.

Clinical history of anterior uveitis and its incidence during the study is also recorded. An ophthalmologic examination is performed at baseline and week 24.

To a subset of patients a MRI scan of sacroiliac joints will be done also at week 24, to assess changes of active inflammatory lesions as detected by MRI.

An extension study of radiological progression is also planned. X-ray changes of sacroiliac joints and lumbosacral spine will be assessed at baseline and at 3 and 5 years.


Recruitment information / eligibility

Status Withdrawn
Enrollment 120
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Inflammatory back pain (definition in Calin et al. JAMA 1977;237:2613-4) as the presenting symptom,

- Positive laboratory test result for HLA-B27,

- Active sacroiliitis in MRI read by qualified radiologist,

- Active disease despite treatment with at least two NSAIDs.

Active disease is defined as:

1. a score of = 30 mm for morning stiffness (average of 2 scores on a 100 mm visual analog scale [VAS] analysing duration and intensity of morning stiffness),

2. scores of = 30 mm VAS for 2 of the following 3 parameters: patient's global assessment of disease activity, back pain and the Bath Ankylosing Spondylitis Functional Index (BASFI).

Exclusion Criteria:

- Known hypersensitivity to methotrexate

- Have received sulfasalazine within 4 weeks prior to the first administration of study agent

- Using oral corticosteroids on a dose equivalent to =10 mg of prednisone/day

- Any concomitant rheumatic disease other than spondyloarthritis

- Fibromyalgia

- Pregnant or breast feeding

- Have had a serious infection within 1 month

- Have any known malignancy or have a history of malignancy within the previous 5 years

- Have current signs or symptoms of severe or uncontrolled renal, hepatic, hematologic, gastrointestinal or pulmonary disease

- Grade 3 or 4 changes in radiographs of sacroiliac joints (grading of radiographs according to the New York criteria)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Methotrexate


Locations

Country Name City State
Finland Rheumatism Foundation Hospital Heinola
Finland Helsinki University Central Hospital Helsinki
Finland Central Finland Central Hospital Jyväskylä
Finland Kuopio University Hospital Kuopio
Finland Tampere University Hospital Tampere

Sponsors (2)

Lead Sponsor Collaborator
Rheumatism Foundation Hospital Orion Corporation, Orion Pharma

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary ASAS20
Secondary ASAS40
Secondary ASAS5/6
Secondary ASAS partial remission
Secondary Incidence of arthritis
Secondary Incidence of anterior uveitis
Secondary BASDAI
See also
  Status Clinical Trial Phase
Completed NCT01208207 - A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) Phase 3
Completed NCT02509026 - Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Phase 4
Completed NCT02704845 - Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain N/A
Terminated NCT01209702 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs Phase 3
Terminated NCT01209689 - A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy Phase 3
Terminated NCT00766402 - An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Phase 4
Completed NCT00000433 - Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Phase 2
Completed NCT00779935 - Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Phase 4
Completed NCT00779012 - A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Phase 4
Completed NCT01863732 - Extension in AS: Sustainability of Benefits, Safety and Tolerability Phase 3
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT01567878 - Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects N/A
Completed NCT01188655 - Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT02159053 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT00202865 - Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) Phase 3
Completed NCT02374502 - Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial N/A
Terminated NCT00273858 - Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis N/A
Completed NCT04810715 - Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis
Completed NCT03880968 - Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis